Increase of KLK7, cytokeratin 5/6, and elafin expression in head and neck squamous cell carcinoma compared with lung squamous cell carcinoma

References

• American Cancer Society Health and Medical Content Team. American Cancer Society. 2023. [cited 2023 Feb]. Available from: https://www.cancer.org/cancer/laryngeal-and-hypopharyngeal-cancer/about/key-statistics.html
   Google Scholar
• Cancer Stat Facts: Tongue Cancer. National institute of health, national cancer institute, surveillance, epidemiology, and end results program. [cited 2023 Feb]. Available from: https://seer.cancer.gov/statfacts/html/tongue.html
   Google Scholar
• Perez-Moreno P, Brambilla E, Thomas R, et al. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012;18(9):2443–51. doi: 10.1158/1078-0432.CCR-11-2370. Epub 2012 Mar 8. PMID: 22407829.
   PubMed Web of Science ®Google Scholar
• Criswell S. Altered expression of epithelial proteins in hidradenitis suppurativa. Clin Exp Dermatol. 2022;13(2):608. https://www.longdom.org/open-access/altered-expression-of-epithelial-proteins-in-hidradenitis-suppurativa-91654.html
   Google Scholar
• Alkemade HA, Molhuizen HO, van Vlijmen-Willems IM, et al. Differential expression of SKALP/Elafin in human epidermal tumors. Am J Pathol. 1993;143(6): 1679–1687. PMID: 8256855; PMCID: PMC1887253.
   PubMed Web of Science ®Google Scholar
• Said JW, Sassoon AF, Shintaku IP, et al. Involucrin in squamous and basal cell carcinomas of the skin: an immunohistochemical study. J Invest Dermatol. 1984;82(5):449–52. doi: 10.1111/1523-1747.ep12260937. PMID: 6210326.
   PubMed Web of Science ®Google Scholar
• van Bommel PF, Kenemans P, Helmerhorst TJ, et al. Expression of cytokeratin 10, 13, and involucrin as prognostic factors in low stage squamous cell carcinoma of the uterine cervix. Cancer. 1994;74(8):2314–2320. doi: 10.1002/1097-0142(19941015)74:8<2314:aid-cncr2820740816>3.0.co;2-1. PMID: 7522949.
   PubMed Web of Science ®Google Scholar
• Meza R, Meernik C, Jeon J, et al. Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLoS One. 2015;10(3):e0121323. doi: 10.1371/journal.pone.0121323. PMID: 25822850; PMCID: PMC4379166.
   PubMed Web of Science ®Google Scholar
• Tatsumori T, Tsuta K, Masai K, et al. p40 is the best marker for diagnosing pulmonary squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2014;22(5):377–382. doi: 10.1097/PAI.0b013e3182980544
   PubMedGoogle Scholar
• Siziopikou K, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007;16(1):104–7. doi: 10.1016/j.breast.2006.09.003. Epub 2006 Nov 13. PMID: 17097880.
   PubMed Web of Science ®Google Scholar
• Taube E, Denkert C, Sehouli J, et al. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma. Hum Pathol. 2017;67:30–36. doi: 10.1016/j.humpath.2017.03.020. Epub 2017 Apr 13. PMID: 28414091.
   PubMed Web of Science ®Google Scholar
• Vlasoff D, Baschinsky D, Frankel W. Cytokeratin 5/6 immunostaining in hepatobiliary and pancreatic neoplasms. Appl Immunohistochem Mol Morphol. 2002;10(2):147–51. doi: 10.1097/00129039-200206000-00009. PMID: 12051633.
   PubMedGoogle Scholar
• Inanc M, Ozkan M, Karaca H, et al. Cytokeratin 5/6, c-met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol. 2014;31(1):801. doi: 10.1007/s12032-013-0801-7. Epub 2013 Dec 11. PMID: 24326984.
   PubMed Web of Science ®Google Scholar
• Abdelrahman A, Rashed H, Abdelgawad M, et al. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer. Ann Diagn Pathol. 2017;28:43–53. doi: 10.1016/j.anndiagpath.2017.01.009. Epub 2017 Feb 4. PMID: 28648939.
   PubMed Web of Science ®Google Scholar
• Wang C, Tsai Y, Jeng Y, et al. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer. PLoS One. 2019;14(8):e0221785. doi: 10.1371/journal.pone.0221785. PMID: 31469885; PMCID: PMC6716637.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cui T, Yang L, et al. The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer. Oncology. 2011;80(5–6):333–40. doi: 10.1159/000329098. Epub 2011 Jul 26. PMID: 21791943.
   PubMed Web of Science ®Google Scholar
• Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116(6):823–30. doi: 10.1309/21TW-2NDG-JRK4-PFJX. PMID: 11764070.
   PubMed Web of Science ®Google Scholar
• Comin C, Novelli L, Cavazza A, et al. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma. Tumori. 2014;100(5):559–67. doi: 10.1700/1660.18182. PMID: 25343553.
   PubMed Web of Science ®Google Scholar
• Argon A, Nart D, Veral A. The value of cytokeratin 5/6, p63 and thyroid transcription factor-1 in adenocarcinoma, squamous cell carcinoma and non-small-cell lung cancer of the lung. Turk Patoloji Derg. 2015;31(2):81–88. doi: 10.5146/tjpath.2015.01302. PMID: 25944390.
   PubMedGoogle Scholar
• Yousef G, Scorilas A, Magklara A, et al. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - genomic characterization, mapping, tissue expression and hormonal regulation. Gene. 2000;254(1–2):119–128. doi: 10.1016/s0378-1119(00)00280-8. PMID: 10974542.
   PubMed Web of Science ®Google Scholar
• Planque C, de Monte M, Guyetant S, et al. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun. 2005;329(4):1260–6. doi: 10.1016/j.bbrc.2005.02.100. PMID: 15766562.
   PubMed Web of Science ®Google Scholar
• Chen E, Zhu H, Yang Y, et al. Analysis of expression and prognosis of KLK7 in ovarian cancer. Open Med (Wars). 2020;15(1):932–939. doi: 10.1515/med-2020-0139. PMID: 33336051; PMCID: PMC7712299.
   PubMedGoogle Scholar
• Walker F, Nicole P, Jallane A, et al. Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. Biol Chem. 2014;395(9):1075–86. doi: 10.1515/hsz-2014-0142. PMID: 25153388.
   Web of Science ®Google Scholar
• Talieri M, Diamandis E, Gourgiotis D, et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost. 2004;91(1):180–6. doi: 10.1160/TH03-05-0261. PMID: 14691584.
   PubMed Web of Science ®Google Scholar
• Robinson P, Markham A, Schalkwijk J, et al. Increased elafin expression in cystic, dysplastic and neoplastic oral tissues. J Oral Pathol Med. 1996;25(3):135–139. doi: 10.1111/j.1600-0714.1996.tb00208.x
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Egami H, Kurizaki T, et al. Immunohistochemical expression of SKALP/Elafin in squamous cell carcinoma of the oesophagus. Br J Cancer. 1997;76(8):1081–1086. doi: 10.1038/bjc.1997.511
   PubMed Web of Science ®Google Scholar
• Westin U, Nyström M, Ljungcrantz I, et al. The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm. 2002;11(1):7–12. doi: 10.1080/09629350210304
   PubMed Web of Science ®Google Scholar
• Yoshida N, Egami H, Yamashita J, et al. Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung. Oncol Rep. 2002;9(3):495–501. doi: 10.3892/or.9.3.495. PMID: 11956616.
   PubMed Web of Science ®Google Scholar